NTLA Intellia Therapeutics Inc
P/E
--
Forward P/E
--
Price/Sales
33.51
Beta
1.815
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Intellia Pops 13.5% on Earnings-Beat Signal — But Can a Pre-Revenue Biotech Justify Its $1.8 Billion Price Tag?
Shares of Intellia Therapeutics surged 13.5% to $14.77 after a Zacks research note flagged the CRISPR gene-editing firm as statistically likely to beat Wall...
🟢 Intellia Therapeutics Inc is trading 13.5% up today on bullish research and expected EPS beat
Intellia Therapeutics Inc is trading 13.5% up today at $14.77 as investors react to fresh bullish research from Zacks ahead of the company's upcoming earnings...